The following research projects led by BC Children's Hospital and BC Women's Hospital researchers are focused on investigating potential treatments for COVID-19, as well as immune responses to COVID-19 vaccines. 

Click on the study titles below for more information. 

CATCO-NOS: Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of Nosocomial Acquired COVID-19 Patients

Srinivas Murthy, Principal Investigator

We will evaluate the clinical effectiveness of bamlanivimab in this patient group. 

Contact: Srinivas Murthy

A Prospective Cohort Study of the Effect of COVID-19 Vaccination in Cancer Patients

Stephen Chia, Principal Investigator

In this study, we'll determine if there is an induced antibody response to the COVID-19 vaccine in cancer patients. We will also assess for significant adverse events to the COVID-19 vaccine in cancer patients, assess the rate of SARS-CoV-2 (COVID-19) infection in cancer patients who have received the COVID-19 vaccine, measure the vaccine-induced T cell response in certain cohorts of cancer patients who have received the COVID-19 vaccine, and assess immune-related gene expression changes in cancer patients who have received the COVID-19 vaccine.

Contact: Stephen Chia

CURE: Countermeasures against COVID-19 Pandemic

Mel Krajden, Principal Investigator

Due to their unmatched specificity, monoclonal antibodies make high-accuracy diagnostics and potent drugs with low side effects. Likewise, antigen-specific B cells specific to a particular antigen, such as SARS-CoV-2, may also be used to develop potent therapeutics to fight disease. Once the DNA sequence encoding for an antibody with desired properties is known, it can be produced in large quantities by recombinant expression in cell lines. Potent antibodies are present in the blood of COVID-19 patients after the infection has been cleared. AbCellera’s technology allows rapid identification of neutralizing antibodies from these convalescent patients and will provide an important tool to accelerate the discovery and development of new therapies.

Individuals who recover from COVID-19 will have a wide breadth and diversity of unique antigen-specific B cells, which will allow identification of high-affinity antibodies with robust neutralizing activity. In this study, we will discover those antibodies, which can be further developed to both prevent progression of disease in the management of acute COVID-19 infection, and potentially contribute passive immune protection in high-risk populations.

Host Response Mediators In Coronavirus (COVID-19) Infection: Is There a Protective Effect Of Losartan on Outcomes of Coronavirus Infection?

James A. Russell, Principal Investigator

This study will address the need for effective treatments for those infected with COVID-19. Specifically, for people like you, that become ill enough to require admission to hospital, we think that an existing drug called losartan might help treat COVID-19 and hasten recovery. As such, we will investigate the safety and effectiveness of losartan in the treatment of COVID-19 and whether it can decrease the rate of death in COVID-19 patients compared to usual care of standard of care (SOC). We will also determine whether losartan can help limit damage to organs (kidney, lung, heart and liver) as this type of damage has been observed in COVID-19 patients in hospital.

Contact: Lynda Lazosky

CATCO: Canadian Treatments for COVID19

Srinivas Murthy, Principal Investigator

A randomized, controlled trial of lopinavir/ritonavir in hospitalized patients with confirmed COVID19.

Contact: Srinivas Murthy

PREVENT-COVID Study

Manish Sadarangani, Principal Investigator

Researchers at the Vaccine Evaluation Center and BC Centre for Disease Control would like to better understand immune responses to COVID-19 vaccines in adults. Multiple COVID-19 vaccines will be used in Canada and best use of these vaccines will help us control the pandemic as quickly as possible. The purpose of this study is to measure the short- and long-term immune responses generated by different COVID-19 vaccines in adults. The goals of the study are to help researchers understand immunity to COVID-19 after vaccination and to help guide policies and recommendations for how these vaccines are used.

For more information: The Vaccine Evaluation Center

Contact: Mistin Wilkinson

CANVAS Surveillance of Adverse Events Following Immunization among Individuals Immunized with the COVID19 Vaccine

Julie Bettinger, Principal Investigator

The Canadian National Vaccine Safety (CANVAS) Network is a national platform that monitors vaccine safety after vaccines are approved for use. We are monitoring the safety of the COVID-19 vaccines in Canada and we need YOUR help.

Using a web-based survey we will collect information about whether or not health events occur after receiving COVID-19 vaccines. We will also collect health events from people who have not received a COVID-19 vaccine.

For more information: The Vaccine Evaluation Center

Contact: Lilah Johnson

Optimizing the clinical management of patients with adverse events following COVID-19 vaccination and potential contraindications to vaccination in the Special Immunization Clinic Network

Manish Sadarangani, Principal Investigator

The overall purpose of this study is to inform the development of a standardized approach to clinical care of patients who have had a medically significant AEFI after COVID-19 vaccination.

Systematic assessment and follow up of patients with medically significant adverse events following COVID-19 vaccines is needed to describe the types of events that come to medical attention, their severity/seriousness and the patient populations affected, to ensure patients who develop AEFIs receive the care they need, and to support public health safety surveillance and rapid evaluation of emerging vaccine safety signals.

For more information: The Vaccine Evaluation Center

Contact: Brittany Seligman

COVID-19 Ring-based Prevention trial with Lopinavir/ritonavir (CORIPREV LR)

Natasha Press, Principal Investigator

The purpose of this study is to evaluate the efficacy of a 14-day course of oral lopinavir/ritonavir (LPV/r) as PEP against microbiologically confirmed COVID-19 among individuals with a significant unprotected exposure to a confirmed case.

Prevention interventions are critical for the trial’s key target populations: frail elderly in congregate living or health care facilities; health care workers; and household/community contacts of confirmed COVID-19 cases. Breaking chains of spread in nursing/retirement/long-term care homes, among healthcare workers, and in the community will be vital to limiting the impact of this disease.

Contact: Natasha Press